Why Vor Biopharma Inc.’s (VOR) Stock Is Down 5.64%
As of Wednesday, August 12, Vor Biopharma Inc.’s VOR share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 5.50%
As of Friday, July 31, Vor Biopharma Inc.’s VOR share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 6.59%
As of Monday, July 27, Vor Biopharma Inc.’s VOR share price has surged by 6.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Vor Biopharma Inc.’s (VOR) Stock Is Down 5.39%
As of Wednesday, July 22, Vor Biopharma Inc.’s VOR share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Vor Biopharma Inc.’s (VOR) Stock Is Up 5.07%
As of Tuesday, July 21, Vor Biopharma Inc.’s VOR share price has surged by 5.07%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | VOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,382.0 | $292.6 | 49% |
|
| Shares Out (Mil) | 54.3 | 54.4 | 49% |
|
| Institutional Ownership | 96.9% | 93.2% | 71% |
|
| Float (Mil) | 37.2 | 40.2 | 41% |
|
| Beta | 1.72 | 0.94 | 88% |
|
| Avg Daily Volume (000s) | 770 | 544 | 65% |
|
| Price Change (52-week) |
(46.9%) | 59.7% | 15% |
|
| Growth | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (74.3%) | (10.1%) | 3% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (61.9%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 5 | |
| Current EPS | ($0.720) | ($6.530) | ($3.812) | |
| Month Ago EPS | ($0.768) | ($6.901) | ($3.742) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.768) | ($6.901) | ($3.742) | |
| Year/Year Chg | (37.8%) | (90.7%) | (94.3%) | |
| Financials | VOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $628 | ($43) | 81% |
|
| EPS (TTM) | $20.192 | ($1.400) | 98% |
|
| Operating Cash Flow (TTM) (Mil) | ($140) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($85) | $2 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $932 | $164 | 40% |
|
| Valuation | VOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | 1.2 | 19.6 | 1% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | 182.9% | (47.5%) | 100% |
|
| ROE | (73.6%) | (55.0%) | 12% |
|
| Liabilities to Assets | 141.6% | 29.6% | 97% |
|
| F-Score | 3 | 3 | 18% |
|
Vor Biopharma Inc. did not pass any screens on 8/21/2026.
